RDY up +5.93% percent right now. $RDY High is at 5
Post# of 250663
Posted On: 11/08/2014 9:33:37 PM
RDY up +5.93% percent right now. $RDY High is at 55.75 and the Low 54.55 with current volume of 356,500.
Recent News posted below.
RDY Dr. Reddy's Laboratories Ltd Recent Headline News
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 91.06 (-3.49), ACT: 245.91 (-4.47), MYL: 53.11 (-0.39), RDY: 55.72 (+3.12)
Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 55.72 (+3.12)
Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 55.72 (+3.12)
Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 55.72 (+3.12)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 50.17 (-0.82), SCMP: 9.25 (+0.09), RDY: 55.72 (+3.12)
Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 55.72 (+3.12)
Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 55.72 (+3.12)
Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 7.84 (-0.18), MYL: 53.11 (-0.39), TEVA: 57.70 (-1.02), RDY: 55.72 (+3.12)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 55.72 (+3.12)
Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 55.72 (+3.12)
Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 55.72 (+3.12)
17.9% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Tue Sep 09, 4:52PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 17.91% as of today's recent price of $48.91.
RDY: 55.72 (+3.12)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 18.5% (RDY)
Comtex SmarTrend(R) - Tue Sep 02, 10:58AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 18.47% as of today's recent price of $49.14.
RDY: 55.72 (+3.12)
Tata Motors, Icici Bank Ride A Strong Week In India
at Investor's Business Daily - Fri Aug 22, 4:57PM CDT
Outside the U.S., most global markets posted a sluggish week. In China, Hong Kong's Hang Seng index and the Shanghai Composite each gained a fraction for the week. Tokyo's Nikkei 225 gained 1.3%, buoyed by strong July Japan exports data and by a...
IBN: 58.01 (-0.82), HDB: 51.84 (-1.05), RDY: 55.72 (+3.12), INFY: 68.00 (+0.42), TTM: 46.54 (-1.01)
Shares of RDY Up 11.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 19, 9:23AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 11.02% as of today's recent price of $46.05.
RDY: 55.72 (+3.12)
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
MNK: 91.06 (-3.49), SLXP: 91.47 (-47.08), ALXN: 193.81 (+0.67), RDY: 55.72 (+3.12)
Impax Shares Plunge Post FDA Inspection of Taiwan Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:15PM CDT
Shares of Impax Laboratories Inc. (IPXL), which fell 15.2% immediately after the company announced that the FDA has inspected its Taiwan facility, continued to fall in the subsequent trading session.
AGN: 196.00 (-1.40), MNK: 91.06 (-3.49), IPXL: 28.57 (-0.19), RDY: 55.72 (+3.12)
Recent News posted below.
RDY Dr. Reddy's Laboratories Ltd Recent Headline News
Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 91.06 (-3.49), ACT: 245.91 (-4.47), MYL: 53.11 (-0.39), RDY: 55.72 (+3.12)
Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 55.72 (+3.12)
Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 55.72 (+3.12)
Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 55.72 (+3.12)
Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 50.17 (-0.82), SCMP: 9.25 (+0.09), RDY: 55.72 (+3.12)
Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 55.72 (+3.12)
Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 55.72 (+3.12)
Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 7.84 (-0.18), MYL: 53.11 (-0.39), TEVA: 57.70 (-1.02), RDY: 55.72 (+3.12)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 55.72 (+3.12)
Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 55.72 (+3.12)
Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 55.72 (+3.12)
17.9% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Tue Sep 09, 4:52PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 17.91% as of today's recent price of $48.91.
RDY: 55.72 (+3.12)
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 18.5% (RDY)
Comtex SmarTrend(R) - Tue Sep 02, 10:58AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 18.47% as of today's recent price of $49.14.
RDY: 55.72 (+3.12)
Tata Motors, Icici Bank Ride A Strong Week In India
at Investor's Business Daily - Fri Aug 22, 4:57PM CDT
Outside the U.S., most global markets posted a sluggish week. In China, Hong Kong's Hang Seng index and the Shanghai Composite each gained a fraction for the week. Tokyo's Nikkei 225 gained 1.3%, buoyed by strong July Japan exports data and by a...
IBN: 58.01 (-0.82), HDB: 51.84 (-1.05), RDY: 55.72 (+3.12), INFY: 68.00 (+0.42), TTM: 46.54 (-1.01)
Shares of RDY Up 11.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 19, 9:23AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 11.02% as of today's recent price of $46.05.
RDY: 55.72 (+3.12)
Dr. Reddy's (RDY) Q1 Earnings and Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 2:20PM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, up 52% and revenues of $586 million, up 24% from the year-ago period .
MNK: 91.06 (-3.49), SLXP: 91.47 (-47.08), ALXN: 193.81 (+0.67), RDY: 55.72 (+3.12)
Impax Shares Plunge Post FDA Inspection of Taiwan Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 4:15PM CDT
Shares of Impax Laboratories Inc. (IPXL), which fell 15.2% immediately after the company announced that the FDA has inspected its Taiwan facility, continued to fall in the subsequent trading session.
AGN: 196.00 (-1.40), MNK: 91.06 (-3.49), IPXL: 28.57 (-0.19), RDY: 55.72 (+3.12)
(0)
(0)